Original from: Fujirebio
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano) announce that they have entered into a Basic Agreement on Business Collaboration to deepen their multifaceted collaboration, such as on research and development, production, clinical development, and sales-marketing, in the field of immunoassay.
Sysmex has built up a robust technological foundation as well as a global network in the in vitro diagnostics field through developing its business in this field for more than 50 years. In order to further reinforce its diagnostics business, the company aims to speed up expansion of its immunochemistry business in the global markets including U.S. and Europe. In recent years, Sysmex has been focusing on activities aimed at developing and providing unique tests that create new value, such as launch of reagents to identify amyloid beta (A¦Â) accumulation in the brain, a cause of Alzheimer's disease, from blood samples in the Japanese and US LDT markets.
Fujirebio has a wide range of reagent raw materials and product portfolios through its long-standing business in the immunoassay. In recent years, in addition to developing its own products, Fujirebio has been reinforcing Contract Development and Manufacturing Organization (CDMO) strategy to promote the global development of unique tests. As part of this initiative, since 2020, Fujirebio, through its subsidiaries, has been developing dedicated reagents for Sysmex's Automated Immunoassay System HISCL™-Series.
The two companies have agreed to deepen their collaboration, based on a common belief that combining their respective expertise and strengths in immunoassay will accelerate their global expansion, and can contribute to the development and advancement of immunoassay. Moving forward, we aim to select themes from a wide range of potential collaborations, such as research and development, production, clinical development, and sales-marketing, and proceed into the execution phase by the end of March 2024.
Fujirebio and Sysmex aim to deliver high value testing to global customers as early as possible driven by strengthened partnership in immunoassay.
